Doing a bit of digging here, it seems hepcidin is typically somewhat low in CHF patients, consistent with chronic HIF upregulation. Of course you would expect HIF to be upregulated in any chronic hypoxic condition.
I don't think the Street has fully appreciated the hepcidin data yet. For example, around half of RA patients have upregulated hepcidin and (likely as a result) chronic anemia. So right there is a massive potential market that nobody has discussed much.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.